Glenmark Pharmaceuticals has announced that Ryaltris olopatadine / mometasone nasal spray was approved by ANVISA earlier this year for the treatment of allergic rhinitis in patients aged 12 and over and that the company has now launched the product in Brazil.
In the US, Ryaltris has been approved for the treatment of seasonal allergic rhinitis in patients aged 12 and over since January 2022, and the FDA recently approved the use of Ryaltris in patients aged 6-12. The nasal spray has also been approved in the EU and UK, Australia, South Korea, Russia, and China.
Glenmark Pharmaceuticals Executive VP and Global Head Marco Cerato commented, “The launch of Ryaltris in Brazil marks a significant milestone for our innovative respiratory portfolio and reflects our continued commitment to advancing respiratory care through science-led innovation and a patient-centric approach. As the largest healthcare market in Latin America, Brazil provides a strategic opportunity to bring this differentiated treatment option to patients and healthcare professionals.”
Read the Glenmark Pharmaceuticals press release
